drugset / Trial / NCT00003920

Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

NCT00003920

Phase 1 Unknown 18 enrolled University of California, Davis
Treatment

Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Cyclosporine may prevent this from happening. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody plus cyclosporine and peripheral stem cell transplantation in treating patients who have metastatic breast cancer that has not responded to previous therapy.

Timeline

Start
1996-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclosporine Peptide Oral
Background filgrastim Protein / enzyme biologic Subcutaneous

Indications